Boston Scientific’s View On Vaginal Mesh Safety
On February 12, 2019, the U.S. Food and Drug Administration (FDA) convened a general issues advisory panel of experts to discuss the safety and effectiveness of transvaginal surgical mesh to treat pelvic organ prolapse (POP). Patient safety is always our highest priority, and we appreciate the panel’s scientific and clinical input. Please see our statement here.
Information for patients
Urogynecological mesh made with polypropylene may be an effective treatment option for women living with stress urinary incontinence and pelvic organ prolapse. Nearly one million women have been successfully treated with Boston Scientific’s mesh.
Information for physicians
We know that recent media reports about mesh may have been concerning to you and your patients.
A message from CEO Mike Mahoney
Patient health, safety and peace-of-mind are what matters to us at Boston Scientific. Recent news media may have been worrisome to women who have urogynecological mesh implants, or may be considering them to treat pelvic floor disorders. Our goal is to answer your questions and provide accurate information. Hear more about the facts on our mesh products from our Chairman and CEO, Mike Mahoney.
ii. Gilbert A., Graham M., Young J. (2004) Polypropylene: the Standard of Mesh Materials. In: Schumpelick V., Nyhus L.M. (eds) Meshes: Benefits and Risks. Springer, Berlin, Heidelberg, pg. 102
iii. Gilbert A., Graham M., Young J. (2004) Polypropylene: the Standard of Mesh Materials. In: Schumpelick V., Nyhus L.M. (eds) Meshes: Benefits and Risks. Springer, Berlin, Heidelberg, pg. 102